<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70535">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01950741</url>
  </required_header>
  <id_info>
    <org_study_id>D-1304-013-014</org_study_id>
    <nct_id>NCT01950741</nct_id>
  </id_info>
  <brief_title>Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy</brief_title>
  <acronym>VAULT</acronym>
  <official_title>An Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Injection of VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pusan National University Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effects of VEGF Trap-Eye (aflibercept) in treatment-naive polypoidal choroidal vasculopathy
      (PCV) will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy of VEGF Trap-Eye (aflibercept, Eylea) for exudative age-related macular
      degeneration (AMD) was demonstrated in the phase III VIEW study. Polypoidal choroidal
      vasculopathy (PCV) is considered as a subtype of exudative AMD, however it is reportedly
      different from choroidal new vessels based on the histologic studies. The aim of this study
      is to evaluate effects of VEGF Trap-Eye in treatment of PCV, which was diagnosed using
      indocyanine green (ICG) angiography. VEGF Trap-Eye will be injected intravitreally bimonthly
      after 3 monthly loading dose for 12 months in treatment-naive PCV patients. The efficacy
      will be evaluated on preserving visual acuity and improving angiographic features at 12
      months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visual acuity reservation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients lose visual acuity less than 3 lines or 15 ETDRS (Early Treatment Diabetic Retinopathy Study) letters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity changes</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean changes of visual acuity in ETDRS letters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity &gt;20/200</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients  having  visual acuity more than 20/200</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity &gt;20/40</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients having visual acuity more than 20/40</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICG angiography</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients having complete resolution  of polypoidal lesion in ICG angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>VFQ (visual function questionaire)-25 score</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Exudative Age-related Macular Degeneration</condition>
  <condition>Polypoidal Choroidal Vasculopathy</condition>
  <arm_group>
    <arm_group_label>aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aflibercept 2 mg is injected into the vitreous cavity. Injections are given monthly three times, then are given bi-monthly to 12 months (month 0, 1, 2, 4, 6, 8, and 10; total 7 injections for 1 year).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aflibercept</intervention_name>
    <description>Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.</description>
    <arm_group_label>aflibercept</arm_group_label>
    <other_name>Eyelea, VEGF Trap-Eye</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Submacular PCV diagnosed using ICG angiography with no previous treatment (branching
             vascular network with or without polypoidal dilation in ICG angiography)

          -  Presence of signs of recent activity of PCV

               1. Visual acuity between 20/40 and 20/320

               2. Active leakage in fluorescein angiography

               3. Presence of any fluid in OCT(optical coherence tomography)-intraretinal,
                  subretinal, sub-retinal pigment epithelial

        Exclusion Criteria:

          1. Extramacular PCV

          2. Subretinal hemorrhage or other retinal lesions blocking angiographic characteristics
             in more than 50% area of PCV lesion.

          3. Previous treatment of intravitreal injections (anti-VEGF, steroid or other agents)

          4. Previous treatment of photodynamic therapy

          5. Previous ocular surgery except cataract surgery before 3 or more months

          6. Presence of exudative AMD in the other eyes requiring anti-VEGF treatment
             (Intravitreal bevacizumab was reported to affect the other eye.)

          7. Presence of other ocular diseases which may affect visual acuity (glaucoma, cataract
             with opacity involving visual axis, etc)

          8. Presence of uncontrolled systemic disease (diabetes mellitus, hypertension, ischemic
             heart disease, cerebral infarction, etc)

          9. Patients who cannot understand or conform to the study protocol.

         10. Patients who refuse to agree to the informed consent.

         11. Patients with contraindication to aflibercept

               -  Ocular or periocular infection

               -  Active severe intraocular inflammation

               -  Known hypersensitivity to aflibercept or to any of the excipients
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Pil Shin, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kyungbuk National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ji Eun Lee, MD, PhD</last_name>
    <phone>+82-51-240-7957</phone>
    <email>jlee@pusan.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Busan Paik Hospital</name>
      <address>
        <city>Busanjin-gu</city>
        <state>Busan</state>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Woong Kim, MD, PhD</last_name>
      <phone>+82-51-890-8746</phone>
      <email>maekbak@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Hyun Woong Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haeundae Paik Hospital</name>
      <address>
        <city>Haeundae</city>
        <state>Busan</state>
        <zip>612-030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo-eun Lee, MD, PhD</last_name>
      <phone>+82-51-797-2310</phone>
      <email>jooeun2@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Joo-eun Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Seo-gu</city>
        <state>Busan</state>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Eun Lee, MD, PhD</last_name>
      <phone>+82-51-240-7957</phone>
      <email>jlee@pusan.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Ji Eun Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Min Kyu Shin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sungwho Park, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gospel Hospital</name>
      <address>
        <city>Seo-gu</city>
        <state>Busan</state>
        <zip>602-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sangjoon Lee, MD, PhD</last_name>
      <phone>+82-10-9335-1487</phone>
      <email>hhiatus@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Sangjoon Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Jung-gu</city>
        <state>Daegu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Pil Shin, MD, PhD</last_name>
      <phone>+82-10-45045801</phone>
      <email>jps11@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Jae Pil Shin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dong Ho Park, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Jung-gu</city>
        <state>Daegu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Cheol Kim, MD, PhD</last_name>
      <phone>+82-53-250-8437</phone>
      <email>eyedr@dsmc.or.kr</email>
    </contact>
    <investigator>
      <last_name>Yu-Cheol Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kwang Soo Kim, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Nam-gu</city>
        <state>Daegu</state>
        <zip>705-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Woohyok Chang, MD, PhD</last_name>
      <phone>+82-53-620-3443</phone>
      <email>changwh@ynu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Woohyok Chang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Min Sagong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gyeongsang National University Hospital</name>
      <address>
        <city>Jinju</city>
        <state>Gyeongsangnam-do</state>
        <zip>660-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inyoung Chung, MD, PhD</last_name>
      <phone>+82-55-750-8728</phone>
      <email>in0chung@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Inyoung Chung, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1432-44.</citation>
    <PMID>17021319</PMID>
  </reference>
  <reference>
    <citation>Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1419-31.</citation>
    <PMID>17021318</PMID>
  </reference>
  <reference>
    <citation>Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012 Dec;119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006. Epub 2012 Oct 17. Erratum in: Ophthalmology. 2013 Jan;120(1):209-10.</citation>
    <PMID>23084240</PMID>
  </reference>
  <reference>
    <citation>Stangos AN, Gandhi JS, Nair-Sahni J, Heimann H, Pournaras CJ, Harding SP. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol. 2010 Nov;150(5):666-73. doi: 10.1016/j.ajo.2010.05.035. Epub 2010 Aug 16.</citation>
    <PMID>20719300</PMID>
  </reference>
  <reference>
    <citation>Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, Weisberger A, Lim TH. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012 Sep;32(8):1453-64.</citation>
    <PMID>22426346</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>September 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pusan National University Hospital</investigator_affiliation>
    <investigator_full_name>Ji Eun Lee</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
